Alphaeon Corporation

Alphaeon Corporation is a privately held healthcare company headquartered in Irvine, California. Its business is oriented toward healthcare providers operating in self-pay segments, where patients commonly pay directly for elective, aesthetic, or otherwise non-covered services rather than relying primarily on traditional health insurance reimbursement. The company has been associated with several provider specialties, including plastic surgery, ophthalmology, dentistry, and dermatology. Alphaeon was founded in July 2013 by Robert E. Grant, who had previously served as the company’s chief executive officer. From its formation, the company’s stated focus was the development of healthcare products and services intended to support providers and patients in self-pay care categories. The available reference material does not provide a complete catalog of Alphaeon-branded medical products, clinical technologies, or service revenues, so the company is best characterized as a healthcare-platform and services organization rather than assigned a narrower product category. The company remains a wholly owned subsidiary of Strathspey Crown LLC, a private equity firm based in Newport Beach, California. This ownership structure distinguishes Alphaeon from a publicly traded healthcare manufacturer: no stock exchange listing or ticker is identified in the available sources. Information about its current leadership, financial performance, geographic expansion, and detailed operating subsidiaries is limited. In January 2020, Alphaeon reorganized its corporate structure into two business units. One became AEON Biopharma, Inc., while the other became Alphaeon1 LLC, doing business as Alphaeon Credit. The reorganization indicates a separation between a biopharmaceutical-oriented business and a financing or payment-services business serving healthcare transactions. Alphaeon Credit is associated with payment options for eligible healthcare services, although the supplied references do not establish a complete description of its current products, terms, or market footprint. The available material likewise does not specify whether AEON Biopharma continued to operate as a direct Alphaeon business unit or subsequently developed an independent corporate identity. Alphaeon’s market positioning is therefore centered on enabling or supporting self-pay healthcare, particularly in specialties where elective procedures, cosmetic services, vision care, dental treatment, and dermatological services may involve substantial out-of-pocket costs. Further details about product launches, advertising campaigns, regulatory matters, litigation, executives, and current corporate status require additional verification.

Alphaeon Corporation was established in July 2013 by Robert E. Grant. The company was created as a healthcare business focused on products and services for healthcare providers serving self-pay patients. Its stated provider markets include plastic surgery, ophthalmology, dentistry, and dermatology—specialties in which elective, aesthetic, or other services may be paid for directly by patients. Alphaeon operated as a wholly owned subsidiary of Strathspey Crown LLC, a private equity firm located in Newport Beach, California. The company’s headquarters were identified as Irvine, California. The available public reference material provides limited detail about Alphaeon’s early commercial development, specific product portfolio, revenue, employee base, or geographic operations beyond its United States orientation. It also does not establish a publicly traded status or identify a stock ticker. A major documented corporate change occurred in January 2020, when Alphaeon completely reorganized its structure into two business units. AEON Biopharma, Inc. represented the biopharmaceutical side of the reorganization, while Alphaeon1 LLC conducted business as Alphaeon Credit. The split suggests an effort to separate healthcare and biopharmaceutical activities from financial services designed to support patient-paid care. Alphaeon Credit is associated with financing or payment services for healthcare transactions, while the supplied sources do not provide enough information to describe the detailed products or later ownership of AEON Biopharma. The available record does not document additional confirmed milestones, major campaigns, scandals, lawsuits, acquisitions, product recalls, or leadership changes. Current operating details and the present relationship among Alphaeon Corporation, AEON Biopharma, and Alphaeon Credit should be independently verified before being treated as current.

• 2020

  Corporate structure reorganized

  [1]Alphaeon Corporationen.wikipedia.org

  Alphaeon reorganized in January 2020 and separated its activities into AEON Biopharma, Inc. and Alphaeon1 LLC, doing business as Alphaeon Credit.

• 2013

  Alphaeon Corporation founded

  [1]Alphaeon Corporationen.wikipedia.org

  Robert E. Grant founded Alphaeon Corporation in July 2013 as a healthcare company serving providers in self-pay specialties.

A healthcare-focused company supporting providers and patients in self-pay segments, with activities spanning elective and specialty care and related payment services.

• Healthcare financing and payment services · 2020

  Alphaeon Credit

  Alphaeon Credit is the business name used by Alphaeon1 LLC after the January 2020 corporate reorganization. It is associated with financing or payment services intended to support patients and providers in self-pay healthcare transactions. The supplied reference does not specify current lending terms, eligibility criteria, product range, or geographic availability.

• Biopharmaceutical business unit · 2020

  AEON Biopharma

  AEON Biopharma, Inc. was established as one of the two business units created through Alphaeon Corporation’s January 2020 restructuring. The available source identifies it as the biopharmaceutical arm but does not provide a sufficiently detailed, verified account of its therapies, development pipeline, commercial products, or current corporate status.

• 2020

  Separation of biopharmaceutical and healthcare-finance activitiesStrategy

  Background

  Alphaeon operated across healthcare-related self-pay markets, including provider specialties such as plastic surgery, ophthalmology, dentistry, and dermatology.

  Action taken

  In January 2020, the company reorganized its corporate structure into AEON Biopharma, Inc. and Alphaeon1 LLC, which operated as Alphaeon Credit.

  Aftermath

  The restructuring created distinct entities or business units for biopharmaceutical activities and healthcare payment services. Further outcomes and the entities’ subsequent corporate relationships are not established by the supplied sources.

  Source

1. 1Alphaeon Corporationen.wikipedia.org